BioCentury | Mar 30, 2021
Finance

March 30 Quick Takes: BioNTech anticipates €9.8B year; plus Immune-Onc, Amgen-Rodeo, Stuart, Bond

...Acceleration Program. Launched in 2016 by serial entrepreneur Guo-Liang Yu and President and CEO Charlene Liao, Immune-Onc...
...lead compound is in Phase I testing for hereditary hemochromatosis.TARGETSHPGD (15-PGDH) – Hydroxyprostaglandin dehydrogenase 15 NAD BC Staff Immune-Onc Therapeutics Inc. Stuart...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

...play’s lead is a first-in-class ILT3 inhibitor   By Virginia Li, Associate Editor Launched in 2016, Immune-Onc...
...CEO Charlene Liao, who led development of 10 NMEs during a 14-year career at Genentech Inc.Immune-Onc Therapeutics Inc.’s...
...T cell suppression and block tumor infiltration. In 2018, a Nature study co-authored by researchers from Immune-Onc...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...and nonhuman primates with no sign of toxicity.Immune-Onc’s...
...– SARS-CoV-2 spike protein Danielle Golovin RG6292, RO7296682 University College London Immune-Onc Therapeutics Inc. Capricor...
BioCentury | Oct 17, 2018
Preclinical News

Immune-Onc, University of Texas discover new AML target

...mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics Inc....
...That antibody, dubbed IO-202, targets leukocyte immunoglobin-like receptor, subfamily B, member 4 (LILRB4; CD85k; ILT3). Immune-Onc...
...T cells, decreased tumor size and increased survival compared with wild-type or isotype antibody control. Immune-Onc...
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...Most recently, Culley was CEO of infectious disease company Artemis Therapeutics Inc. (OTCQB:ATMS). Immunotherapy company Immune-Onc Therapeutics Inc....
...Research and Early Development (gRED) division at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Immune-Onc...
...Philadelphia, Pa.). BC Staff Achaogen Inc. Artemis Therapeutics Inc. Lineage Cell Therapeutics Inc. Deciphera Pharmaceuticals Inc. Gamida Cell Ltd. Genentech Inc. Heron Therapeutics Inc. Immune-Onc Therapeutics Inc. Melinta...
BioCentury | Apr 14, 2017
Company News

Immune-Onc, University of Texas deal

...and commercialize biotherapeutics that Immune-Onc says have applications in cancer immunotherapy and other diseases. Additionally, Immune-Onc...
...the lead antibodies from academic labs while Immune-Onc will advance the candidates through clinical trials. Immune-Onc...
...will advance the candidates through clinical trials. Immune-Onc will retain development rights to future products. Immune-Onc...
BioCentury | Apr 6, 2017
Company News

Albert Einstein Colege of Medicine, Memorial Sloan Kettering and Immune-Onc deal

...granted Immune-Onc exclusive, global rights to develop and commercialize biotherapeutics to treat cancer. Einstein and Immune-Onc...
...New York, N.Y. Immune-Onc Therapeutics Inc. , Palo Alto, Calif. Business: Cancer Nora Weintraub Albert Einstein College of Medicine Immune-Onc Therapeutics Inc. Memorial...
BioCentury | Sep 5, 2016
Financial News

Immune-Onc completes venture financing

Immune-Onc Therapeutics Inc. , Palo Alto, Calif. Business: Cancer Date completed: 2016-09-01 Type: Venture financing Raised: $7 million Investors: Fame Mount; CLI Ventures WIR Staff...
BioCentury | Jun 19, 2006
Clinical News

GV1001: Phase II start

Investigators submitted an application in Norway to begin an open-label Phase II trial in 20 chemotherapy- and radiation-experienced patients with stage IIIA and stage IIIB NSCLC to assess GV1001 plus the adjuvant GM-CSF. Patients will...
Items per page:
1 - 9 of 9
BioCentury | Mar 30, 2021
Finance

March 30 Quick Takes: BioNTech anticipates €9.8B year; plus Immune-Onc, Amgen-Rodeo, Stuart, Bond

...Acceleration Program. Launched in 2016 by serial entrepreneur Guo-Liang Yu and President and CEO Charlene Liao, Immune-Onc...
...lead compound is in Phase I testing for hereditary hemochromatosis.TARGETSHPGD (15-PGDH) – Hydroxyprostaglandin dehydrogenase 15 NAD BC Staff Immune-Onc Therapeutics Inc. Stuart...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

...play’s lead is a first-in-class ILT3 inhibitor   By Virginia Li, Associate Editor Launched in 2016, Immune-Onc...
...CEO Charlene Liao, who led development of 10 NMEs during a 14-year career at Genentech Inc.Immune-Onc Therapeutics Inc.’s...
...T cell suppression and block tumor infiltration. In 2018, a Nature study co-authored by researchers from Immune-Onc...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...and nonhuman primates with no sign of toxicity.Immune-Onc’s...
...– SARS-CoV-2 spike protein Danielle Golovin RG6292, RO7296682 University College London Immune-Onc Therapeutics Inc. Capricor...
BioCentury | Oct 17, 2018
Preclinical News

Immune-Onc, University of Texas discover new AML target

...mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics Inc....
...That antibody, dubbed IO-202, targets leukocyte immunoglobin-like receptor, subfamily B, member 4 (LILRB4; CD85k; ILT3). Immune-Onc...
...T cells, decreased tumor size and increased survival compared with wild-type or isotype antibody control. Immune-Onc...
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...Most recently, Culley was CEO of infectious disease company Artemis Therapeutics Inc. (OTCQB:ATMS). Immunotherapy company Immune-Onc Therapeutics Inc....
...Research and Early Development (gRED) division at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Immune-Onc...
...Philadelphia, Pa.). BC Staff Achaogen Inc. Artemis Therapeutics Inc. Lineage Cell Therapeutics Inc. Deciphera Pharmaceuticals Inc. Gamida Cell Ltd. Genentech Inc. Heron Therapeutics Inc. Immune-Onc Therapeutics Inc. Melinta...
BioCentury | Apr 14, 2017
Company News

Immune-Onc, University of Texas deal

...and commercialize biotherapeutics that Immune-Onc says have applications in cancer immunotherapy and other diseases. Additionally, Immune-Onc...
...the lead antibodies from academic labs while Immune-Onc will advance the candidates through clinical trials. Immune-Onc...
...will advance the candidates through clinical trials. Immune-Onc will retain development rights to future products. Immune-Onc...
BioCentury | Apr 6, 2017
Company News

Albert Einstein Colege of Medicine, Memorial Sloan Kettering and Immune-Onc deal

...granted Immune-Onc exclusive, global rights to develop and commercialize biotherapeutics to treat cancer. Einstein and Immune-Onc...
...New York, N.Y. Immune-Onc Therapeutics Inc. , Palo Alto, Calif. Business: Cancer Nora Weintraub Albert Einstein College of Medicine Immune-Onc Therapeutics Inc. Memorial...
BioCentury | Sep 5, 2016
Financial News

Immune-Onc completes venture financing

Immune-Onc Therapeutics Inc. , Palo Alto, Calif. Business: Cancer Date completed: 2016-09-01 Type: Venture financing Raised: $7 million Investors: Fame Mount; CLI Ventures WIR Staff...
BioCentury | Jun 19, 2006
Clinical News

GV1001: Phase II start

Investigators submitted an application in Norway to begin an open-label Phase II trial in 20 chemotherapy- and radiation-experienced patients with stage IIIA and stage IIIB NSCLC to assess GV1001 plus the adjuvant GM-CSF. Patients will...
Items per page:
1 - 9 of 9